从预期到兑现

Group 1 - The core viewpoint of the article highlights the active performance of Hong Kong pharmaceutical stocks, particularly driven by the $8.85 billion deal from Innovent Biologics, which has led to a 5% increase in its stock price and a rise in several other stocks [1] - The total transaction scale for licensing out innovative drugs in China is projected to reach $135.7 billion by 2025, indicating a significant growth opportunity in the sector [1] - The report from Kaiyuan Securities suggests that the innovative drug sector is transitioning from "scale accumulation" to "value release," indicating a shift in market dynamics [1] Group 2 - The innovative drug sector has experienced a correction over the past two quarters, but the current valuation is considered attractive, suggesting potential investment opportunities [1] - The Hong Kong Stock Connect medical sector is also showing strength, with Xiangcai Securities stating that the pharmaceutical industry is expected to stabilize and recover [1] - The article provides information on the Hong Kong Stock Connect Innovative Drug ETF and the Huabao Medical ETF, indicating the growing interest in these investment vehicles [1]